Figure 5
Figure 5. Immune responses in remission after imatinib after prestimulation. (A) Immune responses in prestimulated remission samples using IFN-γ ELISPOT. Remission samples from P10 stimulated with autologous leukemic cells (■, third column), with lysate from autologous leukemic cells (■), unstimulated remission samples (), and leukemic cells alone (□). Results are shown as median and range. Immune responses in prestimulated remission samples using CFC: (B) 28 months; (C) 32 months. Remission samples from P10 stimulated with autologous leukemic cells (third column), unstimulated remission samples (second column), and leukemic cells alone (first columns). (D) Tumor load from patient P10 over time (○).

Immune responses in remission after imatinib after prestimulation. (A) Immune responses in prestimulated remission samples using IFN-γ ELISPOT. Remission samples from P10 stimulated with autologous leukemic cells (■, third column), with lysate from autologous leukemic cells (■), unstimulated remission samples (), and leukemic cells alone (□). Results are shown as median and range. Immune responses in prestimulated remission samples using CFC: (B) 28 months; (C) 32 months. Remission samples from P10 stimulated with autologous leukemic cells (third column), unstimulated remission samples (second column), and leukemic cells alone (first columns). (D) Tumor load from patient P10 over time (○).

Close Modal

or Create an Account

Close Modal
Close Modal